Clinical Trial Update: Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab in combination with chemotherapy for relapsed or refractory Hodgkin lymphoma; status and results are not clearly posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Combination chemotherapy
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Northwestern University | Conditions: Lymphocyte-Rich Classical Hodgkin Lymphoma, Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma | Phase 2 | Status: UNKNOWN | Results posted: 2023-06-02